Compare HDFC Bank Limited Common Stock (HDB) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HDFC Bank Limited Common Stock vs Natera Inc. Common Stock — how do they compare? HDFC Bank Limited Common Stock trades at $23.05 (market cap $114.94B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: HDFC Bank Limited Common Stock is far larger — about 2× Natera Inc. Common Stock's market cap, and HDFC Bank Limited Common Stock pays a 1.8% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HDFC Bank Limited Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| HDB | NTRA | |
|---|---|---|
Market Cap | $114.94B | $57.03B |
Volume | 6,516,078 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $37.18 | $425.64 |
52-Week Low | $21.84 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $14.23T | $56.18B |
Dividend Yield | 1.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDFC Bank (HDB) trades at $22.76, up 0.8% with neutral technical indicators. The bank maintains strong profitability with 28.24% net income margin and consistent earnings beats. However, significant legal headwinds emerge as multiple class action lawsuits approach deadlines in October 2026, creating investor uncertainty despite solid fundamentals.
While HDB demonstrates financial strength with improving debt-to-asset ratios and positive cash flow projections for 2026, the pending securities litigation represents a material risk. Analyst consensus leans cautious with 67% hold ratings, suggesting investors await legal clarity before more bullish positioning despite attractive valuation metrics.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About HDFC Bank Limited Common Stock
HDFC Bank provides retail, wholesale, and treasury banking services in India. Its offerings include deposits, lending, payments, trade finance, and financial services for individuals and businesses.
Read more on HDB →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
